Recently completed genetic studies,1,2 the largest and most comprehensive of their kind, help resolve schizophrenia’s complex pathobiology. With a preponderance of implicated genes localizing to hippocampal glutamatergic neurons, in particular pathogenic loss-of-function mutations in subunits of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and N-methyl-d-aspartate (NMDA) glutamate receptors, the genetics inform the disorder’s anatomy and its pathophysiology.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Corresponding Author: Scott A. Small, MD, 630 W 168th St, New York, NY 10032 (firstname.lastname@example.org).
Published Online: January 25, 2023. doi:10.1001/jamapsychiatry.2022.3849
Conflict of Interest Disclosures: Dr Small reported other support from Tesarakt and patent pending 63/175,872, docket 01001/009746-US3 and is a cofounder of, consultant for, and equity holder of Retromer Therapeutics. Dr Guo reported being a 10% equity holder as the cofounder of Tesarakt and the following patents pending: 63/255,196 docket 01001/009746-US2; 63/304,211 docket 3970-0031PV01; 63/289,785 docket 3970-0046PV04; 63/404,667 docket 3970-0054PV01; 63/293,290 docket 3970-0047PV01, and US20210150671A1. No other disclosures were reported.
You currently have no searches saved.
You currently have no courses saved.